CA3164500A1 - Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure - Google Patents
Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure Download PDFInfo
- Publication number
- CA3164500A1 CA3164500A1 CA3164500A CA3164500A CA3164500A1 CA 3164500 A1 CA3164500 A1 CA 3164500A1 CA 3164500 A CA3164500 A CA 3164500A CA 3164500 A CA3164500 A CA 3164500A CA 3164500 A1 CA3164500 A1 CA 3164500A1
- Authority
- CA
- Canada
- Prior art keywords
- mydgf
- heart failure
- variant
- hypertrophy
- fragment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Cardiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA3223879A CA3223879A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20153008 | 2020-01-21 | ||
| EP20153008.6 | 2020-01-21 | ||
| PCT/EP2021/051079 WO2021148411A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3223879A Division CA3223879A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3164500A1 true CA3164500A1 (en) | 2021-07-29 |
Family
ID=69187588
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3164500A Pending CA3164500A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
| CA3223879A Pending CA3223879A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3223879A Pending CA3223879A1 (en) | 2020-01-21 | 2021-01-19 | Myeloid-derived growth factor for use in treating or preventing fibrosis, hypertrophy or heart failure |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230059560A1 (https=) |
| EP (1) | EP4093750A1 (https=) |
| JP (1) | JP7777532B2 (https=) |
| KR (1) | KR20220131262A (https=) |
| CN (1) | CN115698048A (https=) |
| AU (1) | AU2021211874A1 (https=) |
| BR (1) | BR112022014272A2 (https=) |
| CA (2) | CA3164500A1 (https=) |
| MX (1) | MX2022008727A (https=) |
| PH (1) | PH12022551792A1 (https=) |
| TW (1) | TW202142254A (https=) |
| WO (1) | WO2021148411A1 (https=) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022066729A1 (en) * | 2020-09-22 | 2022-03-31 | Wisconsin Alumni Research Foundation | Method to inhibit neutrophil recruitment to damaged tissue using myeloid-derived growth factor |
| US20250325704A1 (en) | 2020-12-23 | 2025-10-23 | Boehringer Ingelheim International Gmbh | Viral capsid proteins with specificity to heart tissue cells |
| CN115820829B (zh) * | 2022-03-22 | 2026-04-17 | 中国人民解放军军事科学院军事医学研究院 | Mydgf在防治记忆损伤及其相关疾病中的应用 |
| JP2025518285A (ja) | 2022-06-03 | 2025-06-12 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 骨髄由来増殖因子の組換え発現 |
| JP2025530232A (ja) | 2022-09-08 | 2025-09-11 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 心原性ショックの処置に用いる骨髄由来成長因子 |
| EP4480490A1 (en) * | 2023-06-23 | 2024-12-25 | Medizinische Hochschule Hannover | Brick1 for use in treating myocardial diseases |
| WO2025073372A1 (en) | 2023-10-05 | 2025-04-10 | Boehringer Ingelheim International Gmbh | Recombinant expression of myeloid-derived growth factor |
| TW202539726A (zh) | 2023-12-06 | 2025-10-16 | 德商百靈佳殷格翰國際股份有限公司 | 包含骨髓衍生性生長因子之新穎調配物 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0173552B1 (en) | 1984-08-24 | 1991-10-09 | The Upjohn Company | Recombinant dna compounds and the expression of polypeptides such as tpa |
| AU717542B2 (en) | 1996-06-11 | 2000-03-30 | Merck & Co., Inc. | Synthetic hepatitis C genes |
| WO1998011217A2 (en) * | 1996-09-13 | 1998-03-19 | Sagami Chemical Research Center | HUMAN PROTEINS HAVING SECRETORY SIGNAL SEQUENCES AND DNAs ENCODING THESE PROTEINS |
| JP2001506484A (ja) | 1996-09-13 | 2001-05-22 | 財団法人相模中央化学研究所 | 分泌シグナル配列を有するヒト蛋白質およびそれをコードするｄｎａ |
| CA2503390A1 (en) | 2002-11-01 | 2004-05-21 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| WO2004069173A2 (en) | 2003-01-31 | 2004-08-19 | The Trustees Of The University Of Pennsylvania | Methods for modulating an inflammatory response |
| US20080004232A1 (en) | 2006-05-09 | 2008-01-03 | John Wilkins | Characterization of c19orf10, a Novel Synovial Protein |
| EP2130547A1 (en) | 2008-06-06 | 2009-12-09 | Giuliani International Limited | IL-25 for use in the treatment of inflammatory diseases |
| DK2945642T3 (da) * | 2013-01-17 | 2024-05-27 | Medizinische Hochschule Hannover | Faktor 1 protein til anvendelse i behandling eller forebyggelse af sygdomme |
| JP7405772B2 (ja) * | 2018-05-09 | 2023-12-26 | ケロス セラピューティクス インコーポレイテッド | アクチビンｉｉａ型受容体変異体および同変異体を含む医薬組成物 |
| WO2020176732A1 (en) * | 2019-02-27 | 2020-09-03 | Icahn School Of Medicine At Mount Sinai | TREATMENT OF PULMONARY FIBROSIS WITH SERCA2a GENE THERAPY |
-
2021
- 2021-01-19 US US17/759,056 patent/US20230059560A1/en active Pending
- 2021-01-19 EP EP21701283.0A patent/EP4093750A1/en active Pending
- 2021-01-19 CA CA3164500A patent/CA3164500A1/en active Pending
- 2021-01-19 TW TW110102010A patent/TW202142254A/zh unknown
- 2021-01-19 BR BR112022014272A patent/BR112022014272A2/pt unknown
- 2021-01-19 CN CN202180022864.1A patent/CN115698048A/zh active Pending
- 2021-01-19 JP JP2022544144A patent/JP7777532B2/ja active Active
- 2021-01-19 AU AU2021211874A patent/AU2021211874A1/en active Pending
- 2021-01-19 WO PCT/EP2021/051079 patent/WO2021148411A1/en not_active Ceased
- 2021-01-19 MX MX2022008727A patent/MX2022008727A/es unknown
- 2021-01-19 PH PH1/2022/551792A patent/PH12022551792A1/en unknown
- 2021-01-19 KR KR1020227027546A patent/KR20220131262A/ko active Pending
- 2021-01-19 CA CA3223879A patent/CA3223879A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| PH12022551792A1 (en) | 2023-09-18 |
| EP4093750A1 (en) | 2022-11-30 |
| MX2022008727A (es) | 2022-10-07 |
| AU2021211874A1 (en) | 2022-08-25 |
| WO2021148411A1 (en) | 2021-07-29 |
| JP7777532B2 (ja) | 2025-11-28 |
| KR20220131262A (ko) | 2022-09-27 |
| TW202142254A (zh) | 2021-11-16 |
| JP2023511358A (ja) | 2023-03-17 |
| CN115698048A (zh) | 2023-02-03 |
| US20230059560A1 (en) | 2023-02-23 |
| CA3223879A1 (en) | 2021-07-29 |
| BR112022014272A2 (pt) | 2022-09-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7777532B2 (ja) | 線維化、肥大または心不全の処置または予防における使用のための骨髄由来増殖因子 | |
| Iwanaga et al. | Chronic phospholamban inhibition prevents progressive cardiac dysfunction and pathological remodeling after infarction in rats | |
| Hunley et al. | Update on endothelins–biology and clinical implications | |
| JP2005139121A (ja) | ｐ３８／ＪＴＶ−１を有効成分とする癌治療用薬学的組成物及び癌治療用薬学的組成物のスクリーニング方法 | |
| WO2014111458A2 (en) | Factor 1 protein, factor 2 protein and inhibitors thereof for use in treating or preventing diseases | |
| CN103965342B (zh) | 一种mg53突变体及其突变方法和应用 | |
| US11820981B2 (en) | Modulation of TJP1 expression to regulate regeneration of heart cells | |
| EP3658157A1 (en) | Treatment of heart disease by inhibition of the action of muscle a-kinase anchoring protein (makap) | |
| JP2009019032A (ja) | 血管形成及び心臓血管新生の促進又は阻害 | |
| Yang et al. | LncRNA CCRR maintains Ca2+ homeostasis against myocardial infarction through the FTO-SERCA2a pathway | |
| JPWO2004022753A1 (ja) | アクチン関連新規細胞骨格タンパク質ｌａｃｓ | |
| Xiang et al. | LITAF acts as a novel regulator for pathological cardiac hypertrophy | |
| US11944671B2 (en) | Hippo pathway deficiency reverses systolic heart failure post-infarction | |
| US20100210713A1 (en) | Regeneration and survival of cardiac progenitors and cardiomyocytes with a stretch activated transcription factor | |
| WO2024052564A1 (en) | Myeloid-derived growth factor for use in treating cardiogenic shock | |
| TW201200151A (en) | Methods and compositions related to reduced MET phosphorylation by leukocyte cell-derived chemotaxin 2 in tumor cells | |
| EA053022B1 (ru) | Фактор роста миелоидного происхождения для применения при лечении или профилактике фиброза, гипертрофии или сердечной недостаточности | |
| JP2026506629A (ja) | 心臓機能を改善するための変異体ｙａｐの使用 | |
| CN116925205A (zh) | 激活Hippo信号通路的多肽及其用途 | |
| WO2012152063A1 (zh) | 一种新的肝癌分子标志物视黄酸受体应答蛋白2 | |
| HK40088501A (zh) | 用於治疗或预防纤维化、肥大或心力衰竭的髓源性生长因子 | |
| Yang et al. | Cardiac fibroblasts-specific USP7 drives post-infarction cardiac fibrosis by deubiquitinating Krüppel-like factor 7 to promote myofibroblast activation | |
| Coleman | The pharmacology and physiology of orphan G protein-coupled receptor, GPR37L1 | |
| Kempf et al. | Conditional Transgenic Expression of Fibroblast Growth Factor 9 in the Adult Mouse Heart Reduces Heart Failure Mortality After Myocardial Infarction | |
| Lucas et al. | Gadd45g regulates cardiomyocyte death and post-myocardial infarction left ventricular remodelling |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220823 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240919 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241018 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20241022 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241220 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20241220 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241220 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250423 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250423 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20250711 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20251107 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 5TH ANNIV.) - STANDARD Year of fee payment: 5 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251222 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251222 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20251229 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20251229 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20251229 |